Alfa Cytology

07/30/2026

𝐒𝐨𝐥𝐢𝐝 𝐭𝐮𝐦𝐨𝐫 𝐂𝐀𝐑-𝐓 𝐜𝐞𝐥𝐥𝐬 𝐫𝐚𝐫𝐞𝐥𝐲 𝐟𝐚𝐢𝐥 𝐭𝐨 𝐟𝐢𝐧𝐝 𝐭𝐡𝐞 𝐭𝐮𝐦𝐨𝐫, 𝐛𝐮𝐭 𝐭𝐡𝐞𝐲 𝐟𝐚𝐢𝐥 𝐨𝐧𝐜𝐞 𝐭𝐡𝐞𝐲 𝐠𝐞𝐭 𝐭𝐡𝐞𝐫𝐞.

The immunosuppressive tumor microenvironment (TME) exhausts infiltrating T cells before they can do their job. A recent𝘕𝘢𝘵𝘶𝘳𝘦 𝘉𝘪𝘰𝘮𝘦𝘥𝘪𝘤𝘢𝘭 𝘌𝘯𝘨𝘪𝘯𝘦𝘦𝘳𝘪𝘯𝘨 study addressed this directly by engineering CAR-T cells to secrete 𝐛𝐢𝐟𝐮𝐧𝐜𝐭𝐢𝐨𝐧𝐚𝐥 𝐟𝐮𝐬𝐢𝐨𝐧 𝐩𝐫𝐨𝐭𝐞𝐢𝐧𝐬
- an anti-PD-L1 antibody fragment paired with a cytokine payload (𝐈𝐋-𝟏𝟐, 𝐈𝐋-𝟏𝟓, 𝐨𝐫 𝐚 𝐓𝐆𝐅-β 𝐭𝐫𝐚𝐩) - delivering checkpoint blockade and immune stimulation locally at the tumor site.

Across 𝐩𝐫𝐨𝐬𝐭𝐚𝐭𝐞 𝐚𝐧𝐝 𝐨𝐯𝐚𝐫𝐢𝐚𝐧 𝐜𝐚𝐧𝐜𝐞𝐫 𝐦𝐨𝐝𝐞𝐥𝐬, the anti-PD-L1–IL-12 fusion outperformed the alternatives: improved T-cell trafficking, deeper tumor infiltration, and localized interferon-γ production, with a better safety margin than systemic checkpoint combinations.

This suggests that solid tumor CAR-T success may hinge less on antigen selection alone and more on whether the cell can remodel its own microenvironment on arrival. Alfa Cytology’s alfaCAR-T™ engineering platform supports armored-CAR construct design and payload fusion, backed by characterization services that quantify whether a TME-modulating strategy is actually improving persistence in preclinical models.

𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐚𝐫𝐭𝐢𝐜𝐥𝐞 𝐡𝐞𝐫𝐞: https://www.nature.com/articles/s41551-025-01509-2

𝘍𝘰𝘳 𝘦𝘥𝘶𝘤𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘱𝘶𝘳𝘱𝘰𝘴𝘦𝘴 𝘰𝘯𝘭𝘺. 𝘛𝘩𝘪𝘴 𝘤𝘰𝘯𝘵𝘦𝘯𝘵 𝘥𝘰𝘦𝘴 𝘯𝘰𝘵 𝘤𝘰𝘯𝘴𝘵𝘪𝘵𝘶𝘵𝘦 𝘮𝘦𝘥𝘪𝘤𝘢𝘭 𝘢𝘥𝘷𝘪𝘤𝘦.

CAR-T cells engineered with αPD-L1–IL-12 fusion proteins show antitumour activity in mouse models of prostate and ovarian cancer.

07/28/2026

𝐀 𝐬𝐢𝐧𝐠𝐥𝐞 𝐢𝐧 𝐯𝐢𝐯𝐨 𝐢𝐧𝐣𝐞𝐜𝐭𝐢𝐨𝐧 𝐜𝐚𝐧 𝐧𝐨𝐰 𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐞 𝐟𝐮𝐧𝐜𝐭𝐢𝐨𝐧𝐚𝐥 𝐂𝐀𝐑-𝐓 𝐜𝐞𝐥𝐥𝐬 𝐢𝐧𝐬𝐢𝐝𝐞 𝐭𝐡𝐞 𝐛𝐨𝐝𝐲, meaning no apheresis, no ex vivo manufacturing, no lymphodepleting chemotherapy.

A UCSF-led study (Nyberg, Bernard, Ngo et al., Nature, 2026) used site-specific in vivo T-cell engineering to reprogram T cells directly in situ. The approach generated functional CAR-T activity against lymphoma and multiple myeloma models, and, notably, against a solid sarcoma tumor, a setting where ex vivo CAR-T has struggled to gain traction for a decade.

𝐓𝐡𝐢𝐬 𝐫𝐞𝐟𝐫𝐚𝐦𝐞𝐬 𝐭𝐡𝐞 𝐟𝐢𝐞𝐥𝐝'𝐬 𝐜𝐞𝐧𝐭𝐫𝐚𝐥 𝐛𝐨𝐭𝐭𝐥𝐞𝐧𝐞𝐜𝐤: instead of cell-processing logistics, the limiting variables become vector tropism and payload specificity, which is exactly what determines whether an in vivo CAR-T candidate is durable and safe enough to reach the clinic. Alfa Cytology’s in vivo CAR-T development solutions (targeted viral vectors, LNP delivery) plus functional validation services (cytotoxicity, cytokine profiling, persistence assays) are built to characterize those variables early.

𝐋𝐢𝐧𝐤 𝐭𝐨 𝐭𝐡𝐞 𝐍𝐚𝐭𝐮𝐫𝐞 𝐚𝐫𝐭𝐢𝐜𝐥𝐞: https://doi.org/10.1038/s41586-026-10235-x

𝘍𝘰𝘳 𝘦𝘥𝘶𝘤𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘱𝘶𝘳𝘱𝘰𝘴𝘦𝘴 𝘰𝘯𝘭𝘺. 𝘛𝘩𝘪𝘴 𝘤𝘰𝘯𝘵𝘦𝘯𝘵 𝘥𝘰𝘦𝘴 𝘯𝘰𝘵 𝘤𝘰𝘯𝘴𝘵𝘪𝘵𝘶𝘵𝘦 𝘮𝘦𝘥𝘪𝘤𝘢𝘭 𝘢𝘥𝘷𝘪𝘤𝘦.

Stable and cell-specific transgene expression can be achieved through in vivo site-specific integration of large DNA payloads using a two-vector system of enveloped delivery vehicles and adeno-associated viruses.

07/21/2026

𝐓𝐡𝐫𝐞𝐞 𝐟𝐚𝐢𝐥𝐮𝐫𝐞 𝐦𝐨𝐝𝐞𝐬 𝐫𝐞𝐜𝐮𝐫 𝐚𝐜𝐫𝐨𝐬𝐬 𝐜𝐨𝐧𝐯𝐞𝐧𝐭𝐢𝐨𝐧𝐚𝐥 𝐂𝐀𝐑-𝐓 𝐩𝐫𝐨𝐠𝐫𝐚𝐦𝐬: tumors escape via antigen-loss relapse, T cells exhaust under chronic stimulation and lose persistence, and ex vivo manufacturing adds weeks of turnaround and substantial cost.

𝐀𝐥𝐟𝐚 𝐂𝐲𝐭𝐨𝐥𝐨𝐠𝐲'𝐬 𝐭𝐡𝐫𝐞𝐞 𝐧𝐞𝐱𝐭-𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐨𝐧 𝐩𝐥𝐚𝐭𝐟𝐨𝐫𝐦𝐬 target each limitation directly rather than treating them as inherent to the modality.

𝐃𝐮𝐚𝐥-𝐓𝐚𝐫𝐠𝐞𝐭𝐢𝐧𝐠 𝐂𝐀𝐑-𝐓 𝐏𝐥𝐚𝐭𝐟𝐨𝐫𝐦 addresses antigen escape through three validated architectures:
◆ 𝐌𝐢𝐱𝐞𝐝 𝐂𝐀𝐑-𝐓: Two separate CAR-T products co-infused, independent OR-logic activation
◆ 𝐌𝐮𝐥𝐭𝐢-𝐓𝐚𝐫𝐠𝐞𝐭 𝐂𝐀𝐑-𝐓: One cell co-expressing two CAR constructs for robust signal synergy
◆ 𝐓𝐚𝐧𝐝𝐞𝐦 𝐂𝐀𝐑-𝐓 (𝐓𝐚𝐧𝐂𝐀𝐑): Two scFv domains linked within a single compact receptor

Layered on top, Logic-Gate CAR-T (AND/OR/NOT Boolean control) and the SUPRA CAR system (modular ZipCAR/ZipFv antigen-swapping via leucine-zipper pairing) extend programmable specificity without re-engineering the T cell.

𝐜𝐢𝐫𝐜𝐑𝐍𝐀 𝐂𝐀𝐑-𝐓 𝐒𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬 addresses exhaustion and limited persistence by encoding the CAR on a circular, non-integrating RNA:
◆ Cap-independent, IRES/m⁶A-driven translation resists exonuclease degradation, sustaining stable CAR surface density
◆ miRNA and RNA-binding protein sponging eases PD-1/PD-L1-driven dysfunction and stabilizes pro-effector programs
◆ Re-doseable, tunable expression supports both solid tumor and hematologic applications, including BCMA-directed myeloma programs and CD19/CD22/CD20/CD38-directed leukemia/lymphoma constructs

𝐈𝐧 𝐕𝐢𝐯𝐨 𝐂𝐀𝐑-𝐓 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐒𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬 addresses manufacturing turnaround by generating functional CAR-T cells directly within the body:
◆ 𝐓𝐚𝐫𝐠𝐞𝐭𝐞𝐝 𝐯𝐢𝐫𝐚𝐥 𝐯𝐞𝐜𝐭𝐨𝐫𝐬 (𝐥𝐞𝐧𝐭𝐢𝐯𝐢𝐫𝐮𝐬, 𝐀𝐀𝐕): High transduction efficiency (60–80% in preclinical models), durable integration
◆ 𝐓𝐚𝐫𝐠𝐞𝐭𝐞𝐝 𝐧𝐚𝐧𝐨𝐩𝐚𝐫𝐭𝐢𝐜𝐥𝐞 𝐬𝐲𝐬𝐭𝐞𝐦𝐬 (𝐋𝐍𝐏𝐬, 𝐩𝐨𝐥𝐲𝐦𝐞𝐫𝐢𝐜 𝐜𝐚𝐫𝐫𝐢𝐞𝐫𝐬, 𝐞𝐱𝐨𝐬𝐨𝐦𝐞𝐬): Transient, non-integrating, re-dosable expression with low immunogenicity
◆ Eliminates the ex vivo collection-and-culture step entirely, reducing production time from weeks to days

Each platform is evaluated against your program's specific bottleneck, whether that's tumor heterogeneity, T-cell exhaustion in a hostile TME, or the cost and timeline pressure of conventional manufacturing.

Partner with us to accelerate your CAR-T cell therapy development: https://www.alfacytology.com/car-t/dual-targeting-car-t-platform.html

07/17/2026

Confirming that a CAR is expressed on the cell surface tells you the transduction worked. It tells you nothing about whether that cell will still be functionally cytotoxic after repeated antigen stimulation, what its memory-versus-exhaustion balance looks like, or how it will behave once infused into a living immune system. Closing that gap is the purpose of rigorous CAR-T characterization.

𝐚𝐥𝐟𝐚𝐂𝐀𝐑-𝐓™ 𝐂𝐞𝐥𝐥 𝐂𝐡𝐚𝐫𝐚𝐜𝐭𝐞𝐫𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐬𝐩𝐚𝐧𝐬 𝐛𝐨𝐭𝐡 𝐞𝐱𝐩𝐞𝐫𝐢𝐦𝐞𝐧𝐭𝐚𝐥 𝐭𝐢𝐞𝐫𝐬:

𝑰𝒏 𝒗𝒊𝒕𝒓𝒐 𝐜𝐡𝐚𝐫𝐚𝐜𝐭𝐞𝐫𝐢𝐳𝐚𝐭𝐢𝐨𝐧:
◆ 𝐄𝐱𝐩𝐚𝐧𝐬𝐢𝐨𝐧 𝐦𝐨𝐧𝐢𝐭𝐨𝐫𝐢𝐧𝐠: High-throughput image-based cytometry tracking proliferation and cell size during manufacturing
◆ 𝐂𝐲𝐭𝐨𝐭𝐨𝐱𝐢𝐜𝐢𝐭𝐲 𝐚𝐬𝐬𝐞𝐬𝐬𝐦𝐞𝐧𝐭: Image cytometry and bioluminescence-based assays confirming specificity and potency against target cells
◆ 𝐏𝐡𝐞𝐧𝐨𝐭𝐲𝐩𝐢𝐜 𝐩𝐫𝐨𝐟𝐢𝐥𝐢𝐧𝐠: Memory T-cell distribution, activation status, and exhaustion marker characterization
◆ 𝐅𝐮𝐧𝐜𝐭𝐢𝐨𝐧𝐚𝐥 𝐚𝐬𝐬𝐚𝐲𝐬: IFN-γ and other immune activation marker quantification confirming the engineered response

𝑰𝒏 𝒗𝒊𝒗𝒐 𝐜𝐡𝐚𝐫𝐚𝐜𝐭𝐞𝐫𝐢𝐳𝐚𝐭𝐢𝐨𝐧:
◆ 𝐓-𝐜𝐞𝐥𝐥 𝐩𝐞𝐫𝐬𝐢𝐬𝐭𝐞𝐧𝐜𝐞 𝐚𝐧𝐝 𝐛𝐢𝐨𝐝𝐢𝐬𝐭𝐫𝐢𝐛𝐮𝐭𝐢𝐨𝐧: Post-infusion longevity and tumor-homing capacity
◆ 𝐓𝐮𝐦𝐨𝐫 𝐢𝐧𝐟𝐢𝐥𝐭𝐫𝐚𝐭𝐢𝐨𝐧 𝐚𝐬𝐬𝐞𝐬𝐬𝐦𝐞𝐧𝐭: Biopsy and imaging-based localization and tumor eradication monitoring
◆ 𝐒𝐚𝐟𝐞𝐭𝐲 𝐚𝐧𝐝 𝐭𝐨𝐱𝐢𝐜𝐢𝐭𝐲 𝐩𝐫𝐨𝐟𝐢𝐥𝐢𝐧𝐠: Cytokine release syndrome (CRS) and neurotoxicity (ICANS) surveillance, predicting and mitigating risk before clinical translation

This characterization framework supports CAR-T development across six application areas: hematologic malignancies (targeting antigens like CD19 in leukemia and lymphoma), solid tumors (targeting tumor-associated antigens despite TME infiltration barriers), relapsed or refractory cancers resistant to conventional therapy, multi-antigen targeting strategies that reduce antigen-escape risk, autoimmune diseases (eliminating aberrant immune cell populations in conditions like lupus or rheumatoid arthritis), and virus-associated cancers such as HPV-related cervical cancer.

Comprehensive characterization data isn't just a quality checkpoint but the foundation for predicting clinical outcome, optimizing the manufacturing process, and supporting regulatory submission.
Discuss how your CAR-T cell products can perform at their best.

Visit https://www.alfacytology.com/car-t/car-t-cell-characterization.html and contact us at [email protected] or (516) 880-2558.

07/15/2026

A chimeric antigen receptor isn't one fixed molecule but four independently tunable domains, and the choices made at each one determine whether a CAR-T construct activates with precision or fails outright. Alfa Cytology's alfaCAR-T™ platform treats CAR design as a true engineering problem, not a template to be copied.

𝐂𝐀𝐑-𝐓 𝐂𝐞𝐥𝐥 𝐃𝐞𝐬𝐢𝐠𝐧 optimizes each structural component individually:
◆ 𝐀𝐧𝐭𝐢𝐠𝐞𝐧-𝐛𝐢𝐧𝐝𝐢𝐧𝐠 𝐝𝐨𝐦𝐚𝐢𝐧 (𝐬𝐜𝐅𝐯): Computationally modeled for high affinity and specificity, with sequences optimized to reduce immunogenicity and self-aggregation
◆ 𝐇𝐢𝐧𝐠𝐞 𝐚𝐧𝐝 𝐭𝐫𝐚𝐧𝐬𝐦𝐞𝐦𝐛𝐫𝐚𝐧𝐞 𝐝𝐨𝐦𝐚𝐢𝐧: Customized based on target antigen spatial distribution, with transmembrane domains selected to enhance receptor anchoring and surface expression
◆ 𝐂𝐨-𝐬𝐭𝐢𝐦𝐮𝐥𝐚𝐭𝐨𝐫𝐲 𝐚𝐧𝐝 𝐬𝐢𝐠𝐧𝐚𝐥𝐢𝐧𝐠 𝐝𝐨𝐦𝐚𝐢𝐧: CD28, 4-1BB, ICOS, or CD27 integrated with the CD3ζ motif to balance rapid activation against long-term persistence and memory formation

Beyond the basic receptor, four innovative CAR formats extend functional control: 𝐝𝐮𝐚𝐥-𝐭𝐚𝐫𝐠𝐞𝐭 𝐂𝐀𝐑-𝐓 (simultaneous multi-antigen recognition), 𝐥𝐨𝐠𝐢𝐜-𝐠𝐚𝐭𝐞 𝐂𝐀𝐑𝐬 (Boolean AND/OR/NOT control over activation), 𝐭𝐚𝐧𝐝𝐞𝐦 𝐂𝐀𝐑-𝐓 (two antigen-recognition domains in one receptor), and 𝐚𝐫𝐦𝐨𝐫𝐞𝐝 𝐂𝐀𝐑-𝐓 (cytokine or co-stimulatory payload delivery for improved survival in hostile tumor microenvironments).

Once a construct is finalized, 𝐂𝐀𝐑-𝐓 𝐂𝐞𝐥𝐥 𝐄𝐧𝐠𝐢𝐧𝐞𝐞𝐫𝐢𝐧𝐠 carries it through the full cellular production workflow: PBMC-derived T-cell isolation and enrichment, CD3ζ/CD28-mediated activation, viral (lentivirus, AAV) or non-viral (LNP, polymer nanoparticle) gene delivery, and bioreactor-controlled expansion with precise cytokine and co-stimulatory signal management.

The result is the structural basis for alfaCAR-T™'s defining advantage over conventional constructs: engineered for extended anti-tumor durability, enhanced memory T-cell formation, and improved resilience against tumor microenvironment-driven immunosuppression.

𝐑𝐞𝐚𝐝𝐲 𝐭𝐨 𝐭𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦 𝐲𝐨𝐮𝐫 𝐂𝐀𝐑-𝐓 𝐜𝐞𝐥𝐥 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐰𝐢𝐭𝐡 𝐭𝐡𝐞 𝐥𝐚𝐭𝐞𝐬𝐭 𝐢𝐧 𝐚𝐝𝐯𝐚𝐧𝐜𝐞𝐝 𝐞𝐧𝐠𝐢𝐧𝐞𝐞𝐫𝐢𝐧𝐠? 𝐕𝐢𝐬𝐢𝐭:
https://www.alfacytology.com/car-t/car-t-cell-design.html
𝐨𝐫 𝐜𝐨𝐧𝐭𝐚𝐜𝐭 𝐮𝐬 𝐚𝐭: [email protected] and (516) 880-2558

07/10/2026

Oncolytic bacteria release tumor antigens upon tumor cell lysis and actively remodel the tumor microenvironment, creating conditions that enhance the efficacy of complementary therapies. This dual mechanism positions oncolytic bacteria as an ideal combination partner rather than a standalone therapeutic approach. Preclinical studies and early-phase clinical research have shown improved efficacy with these combination strategies, supporting their continued development for treating complex, therapy-resistant cancers.

𝐀𝐥𝐟𝐚 𝐂𝐲𝐭𝐨𝐥𝐨𝐠𝐲'𝐬 𝐎𝐧𝐜𝐨𝐥𝐲𝐭𝐢𝐜 𝐁𝐚𝐜𝐭𝐞𝐫𝐢𝐚-𝐁𝐚𝐬𝐞𝐝 𝐒𝐲𝐧𝐞𝐫𝐠𝐢𝐬𝐭𝐢𝐜 𝐂𝐨𝐦𝐛𝐢𝐧𝐚𝐭𝐢𝐨𝐧 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐏𝐥𝐚𝐭𝐟𝐨𝐫𝐦 supports four validated combination strategies:

◆ 𝐂𝐡𝐞𝐜𝐤𝐩𝐨𝐢𝐧𝐭 𝐢𝐧𝐡𝐢𝐛𝐢𝐭𝐨𝐫 𝐜𝐨𝐦𝐛𝐢𝐧𝐚𝐭𝐢𝐨𝐧𝐬: Bacterial colonization increases tumor antigen presentation and drives local immune activation, helping overcome resistance mechanisms that limit checkpoint blockade as monotherapy.
◆ 𝐁𝐢𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐚𝐧𝐭𝐢𝐛𝐨𝐝𝐲 𝐜𝐨𝐦𝐛𝐢𝐧𝐚𝐭𝐢𝐨𝐧𝐬: Pairing bacterial tumor targeting with bispecific-mediated T cell engagement enables precise, dual-pronged tumor cell elimination.
◆ 𝐂𝐀𝐑-𝐓 𝐜𝐞𝐥𝐥 𝐜𝐨𝐦𝐛𝐢𝐧𝐚𝐭𝐢𝐨𝐧𝐬: Engineered bacteria deliver cytokines or co-stimulatory molecules directly into the tumor microenvironment, supporting CAR-T persistence and function in an environment that otherwise suppresses adoptive cell therapy.
◆ 𝐑𝐚𝐝𝐢𝐚𝐭𝐢𝐨𝐧 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐜𝐨𝐦𝐛𝐢𝐧𝐚𝐭𝐢𝐨𝐧𝐬: Radiation-induced DNA damage sensitizes tumor cells to bacterial action, while bacteria mitigate radiation-induced fibrosis and enhance immune cell infiltration.

𝐃𝐢𝐬𝐜𝐮𝐬𝐬 𝐚 𝐜𝐨𝐦𝐛𝐢𝐧𝐚𝐭𝐢𝐨𝐧 𝐫𝐞𝐠𝐢𝐦𝐞𝐧 𝐟𝐨𝐫 𝐲𝐨𝐮𝐫 𝐨𝐧𝐜𝐨𝐥𝐲𝐭𝐢𝐜 𝐛𝐚𝐜𝐭𝐞𝐫𝐢𝐚 𝐩𝐫𝐨𝐠𝐫𝐚𝐦 𝐰𝐢𝐭𝐡 𝐮𝐬. 𝐕𝐢𝐬𝐢𝐭: https://www.alfacytology.com/oncobact/oncolytic-bacteria-based-synergistic-combination-therapy-platform.html

07/08/2026

Even if a genetically engineered strain efficiently lyses tumor cells in a 2D co-culture, critical questions remain: How does it distribute throughout the body? Can it be cleared from non-target tissues? How does it interact with an intact immune system? Those questions can only be answered 𝘪𝘯 𝘷𝘪𝘷𝘰.

𝑰𝒏 𝒗𝒊𝒕𝒓𝒐 𝐟𝐮𝐧𝐜𝐭𝐢𝐨𝐧𝐚𝐥 𝐯𝐚𝐥𝐢𝐝𝐚𝐭𝐢𝐨𝐧 provides the controlled, rapid-iteration environment needed to de-risk a candidate strain before committing to animal studies:
◆ 𝐂𝐞𝐥𝐥 𝐯𝐢𝐚𝐛𝐢𝐥𝐢𝐭𝐲 𝐚𝐬𝐬𝐚𝐲𝐬: MTT and CCK-8 assays quantifying bacterial impact on tumor cell viability
◆ 𝐂𝐲𝐭𝐨𝐭𝐨𝐱𝐢𝐜𝐢𝐭𝐲 𝐚𝐧𝐚𝐥𝐲𝐬𝐢𝐬: LDH release and Annexin V-FITC assays characterizing the mechanism of induced cell death
◆ 𝐆𝐞𝐧𝐞 𝐞𝐱𝐩𝐫𝐞𝐬𝐬𝐢𝐨𝐧 𝐚𝐧𝐚𝐥𝐲𝐬𝐢𝐬: qPCR and Western blot tracking how bacterial gene expression shifts in the presence of tumor cells
◆ 𝐈𝐦𝐦𝐮𝐧𝐞 𝐫𝐞𝐬𝐩𝐨𝐧𝐬𝐞 𝐞𝐯𝐚𝐥𝐮𝐚𝐭𝐢𝐨𝐧: ELISA and flow cytometry quantifying immune activation, informing combination therapy design

𝑰𝒏 𝒗𝒊𝒗𝒐 𝐞𝐟𝐟𝐢𝐜𝐚𝐜𝐲 𝐞𝐯𝐚𝐥𝐮𝐚𝐭𝐢𝐨𝐧 then confirms tumor-targeting specificity, therapeutic efficacy, and biosafety, across a model library:
◆ 𝐎𝐫𝐭𝐡𝐨𝐭𝐨𝐩𝐢𝐜 𝐦𝐨𝐝𝐞𝐥𝐬: Accurate simulation of the clinical tumor growth microenvironment
◆ 𝐌𝐞𝐭𝐚𝐬𝐭𝐚𝐬𝐢𝐬 𝐦𝐨𝐝𝐞𝐥𝐬: Assessment of distant lesion inhibition and immune memory induction
◆ 𝐏𝐃𝐗 𝐦𝐨𝐝𝐞𝐥𝐬: Patient-representative tumor heterogeneity, with quantified tumor infiltration rate (T/B ratio) and IFN-γ levels
◆ 𝐃𝐫𝐮𝐠-𝐫𝐞𝐬𝐢𝐬𝐭𝐚𝐧𝐭/𝐫𝐞𝐟𝐫𝐚𝐜𝐭𝐨𝐫𝐲 𝐭𝐮𝐦𝐨𝐫 𝐦𝐨𝐝𝐞𝐥𝐬: Ideal for testing combination strategies designed to overcome treatment resistance

𝐂𝐨𝐫𝐞 𝐨𝐮𝐭𝐩𝐮𝐭𝐬 𝐢𝐧𝐜𝐥𝐮𝐝𝐞 oncolytic efficiency validation (tumor volume kinetics, metastasis inhibition, TME remodeling) and targeting specificity verification (quantitative organ-level bacterial distribution and non-target tissue clearance), generated using bioluminescence, MRI, and PET-CT colonization tracking alongside histopathological analysis.

𝐅𝐨𝐫 𝐚𝐧 𝒊𝒏 𝒗𝒊𝒕𝒓𝒐 𝐨𝐫 𝒊𝒏 𝒗𝒊𝒗𝒐 𝐯𝐚𝐥𝐢𝐝𝐚𝐭𝐢𝐨𝐧 𝐬𝐭𝐮𝐝𝐲 𝐟𝐨𝐫 𝐲𝐨𝐮𝐫 𝐞𝐧𝐠𝐢𝐧𝐞𝐞𝐫𝐞𝐝 𝐬𝐭𝐫𝐚𝐢𝐧, 𝐜𝐨𝐧𝐭𝐚𝐜𝐭 𝐮𝐬 𝐡𝐞𝐫𝐞: https://www.alfacytology.com/oncobact/in-vivo-efficacy-evaluation.html

07/07/2026

Without genetic modification, a bacterium that naturally colonizes hypoxic tumor tissue carries native toxicity genes, lacks a mechanism to deliver a therapeutic payload, and has no built-in safeguard ensuring it can be cleared. 𝐀𝐥𝐟𝐚 𝐂𝐲𝐭𝐨𝐥𝐨𝐠𝐲’𝐬 𝐎𝐧𝐜𝐨𝐁𝐚𝐜𝐭™ 𝐩𝐥𝐚𝐭𝐟𝐨𝐫𝐦 𝐜𝐥𝐨𝐬𝐞𝐬 𝐭𝐡𝐢𝐬 𝐥𝐢𝐦𝐢𝐭𝐚𝐭𝐢𝐨𝐧.

Bacterial strain screening begins the process with a curated, rigorously characterized strain library:
◆ 𝑺𝒂𝒍𝒎𝒐𝒏𝒆𝒍𝒍𝒂: Naturally tumor-tropic, low pathogenicity, straightforward to engineer
◆ 𝑪𝒍𝒐𝒔𝒕𝒓𝒊𝒅𝒊𝒖𝒎: Strict anaerobe, ideal for colonizing pronounced hypoxic tumor cores
◆ 𝑬. 𝒄𝒐𝒍𝒊: Efficient gene expression and multi-payload delivery capacity
◆ 𝑳𝒊𝒔𝒕𝒆𝒓𝒊𝒂 𝒎𝒐𝒏𝒐𝒄𝒚𝒕𝒐𝒈𝒆𝒏𝒆𝒔: Intrinsically immunostimulatory, suited to combination immunotherapy designs

𝐄𝐚𝐜𝐡 𝐬𝐭𝐫𝐚𝐢𝐧 𝐢𝐬 𝐞𝐯𝐚𝐥𝐮𝐚𝐭𝐞𝐝 𝐚𝐠𝐚𝐢𝐧𝐬𝐭 𝐟𝐢𝐯𝐞 𝐜𝐫𝐢𝐭𝐞𝐫𝐢𝐚: tumor microenvironment targeting and specificity, pathogenicity/toxicity safety profile, oncolytic activity, immunomodulatory capacity, and genetic engineering tractability.

Genetic engineering in bacteria then transforms the selected strain into a functional therapeutic across three design dimensions:
◆ 𝐇𝐲𝐩𝐨𝐱𝐢𝐚/𝐚𝐜𝐢𝐝-𝐫𝐞𝐬𝐩𝐨𝐧𝐬𝐢𝐯𝐞 𝐭𝐚𝐫𝐠𝐞𝐭𝐢𝐧𝐠: Genetic circuits engineered to activate specifically under the low-oxygen, low-pH conditions unique to the tumor core, keeping the bacterium dormant in healthy, normoxic tissue
◆ 𝐌𝐮𝐥𝐭𝐢𝐦𝐨𝐝𝐚𝐥 𝐩𝐚𝐲𝐥𝐨𝐚𝐝 𝐝𝐞𝐥𝐢𝐯𝐞𝐫𝐲: Engineered capacity to carry and release cytokines, oncolytic enzymes, or antibodies directly at the tumor site, enhanced where appropriate with nanoparticle or carrier technologies
◆ 𝐃𝐮𝐚𝐥-𝐥𝐚𝐲𝐞𝐫 𝐛𝐢𝐨𝐬𝐚𝐟𝐞𝐭𝐲 𝐜𝐨𝐧𝐭𝐫𝐨𝐥: Toxicity gene elimination combined with toxin-antitoxin systems, ensuring the engineered strain can be effectively cleared from the host after completing its therapeutic function

𝐑𝐞𝐚𝐝𝐲 𝐭𝐨 𝐩𝐮𝐫𝐬𝐮𝐞 𝐚 𝐠𝐞𝐧𝐞𝐭𝐢𝐜 𝐜𝐢𝐫𝐜𝐮𝐢𝐭 𝐝𝐞𝐬𝐢𝐠𝐧 𝐟𝐨𝐫 𝐲𝐨𝐮𝐫 𝐩𝐫𝐨𝐠𝐫𝐚𝐦? 𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐮𝐬 𝐚𝐭 [email protected] 𝐨𝐫 (516) 441-0170.

𝐕𝐢𝐬𝐢𝐭: https://www.alfacytology.com/oncobact/genetic-engineering-in-bacteria.html

07/02/2026

The tumor contexts that most urgently need next-generation T-cell therapies are precisely the ones where CAR-T consistently underperforms: 𝐢𝐦𝐦𝐮𝐧𝐨𝐬𝐮𝐩𝐩𝐫𝐞𝐬𝐬𝐢𝐯𝐞 𝐬𝐨𝐥𝐢𝐝 𝐭𝐮𝐦𝐨𝐫𝐬 where T cells exhaust and fail to persist, 𝐡𝐞𝐦𝐚𝐭𝐨𝐥𝐨𝐠𝐢𝐜 𝐦𝐚𝐥𝐢𝐠𝐧𝐚𝐧𝐜𝐢𝐞𝐬 where CRS risk constraints dosing, and 𝐢𝐦𝐦𝐮𝐧𝐨𝐥𝐨𝐠𝐢𝐜𝐚𝐥𝐥𝐲 𝐜𝐨𝐥𝐝 𝐭𝐮𝐦𝐨𝐫𝐬 where T-cell exclusion prevents any adoptive therapy from engaging. ETES™ was built with these contexts as the primary design constraints and has shown in vitro and in vivo efficacy.

𝑰𝒏 𝒗𝒊𝒕𝒓𝒐 𝐄𝐟𝐟𝐢𝐜𝐚𝐜𝐲 𝐄𝐯𝐚𝐥𝐮𝐚𝐭𝐢𝐨𝐧:
◆ Antigen-specific cytotoxicity in 2D co-culture with TAA-positive and TAA-negative target cells confirms selectivity and E:T dose-response
◆ 3D tumor spheroid infiltration and killing assays
◆ Multiplex cytokine profiling under antigen-stimulated conditions: IFN-γ, IL-2, TNF-α, Granzyme B
◆ Persistence and proliferation kinetics across stimulation cycles

𝑰𝒏 𝒗𝒊𝒗𝒐 𝐄𝐟𝐟𝐢𝐜𝐚𝐜𝐲 𝐄𝐯𝐚𝐥𝐮𝐚𝐭𝐢𝐨𝐧:
◆ Syngeneic, xenograft, and humanized mouse tumor models with study design matched to tumor type and clinical relevance
◆ ETES™ vs. untreated and CAR-T comparator cohorts with longitudinal tumor volume measurement
◆ ETES™ T-cell biodistribution and tumor infiltration quantified by FACS and IHC on excised tissue
◆ Persistence tracking over study duration confirming the T-cell longevity advantage of physiological TCR signaling
◆ GvHD monitoring and histopathology to support IND-enabling safety data packages

𝐓𝐮𝐦𝐨𝐫 𝐚𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐚𝐝𝐯𝐚𝐧𝐭𝐚𝐠𝐞𝐬:
◆ Solid tumors: Conditional activation sustains effector function under chronic TME immunosuppression
◆ Hematologic malignancies: Antigen-gated co-receptor domain structurally reduces CRS risk
◆ Cold tumors: Multi-antigen and conditional modules convert immunologically excluded contexts into actionable targets

𝐋𝐞𝐚𝐫𝐧 𝐦𝐨𝐫𝐞: https://www.alfacytology.com/etes/t-cell-engineering.html

07/01/2026

An ETES™ module with precisely engineered binding domains and conditional activation logic only performs as intended if the T cells carrying it retain phenotypic fitness, functional potency, and consistent ETES expression after engineering and expansion. Each of those attributes can be compromised independently through inefficient delivery, suboptimal culture conditions, or inadequate process monitoring.

Alfa Cytology’s ETES™ T-cell Engineering and Manufacturing services span the full production chain from primary T-cell isolation through preclinical-ready batch delivery.

𝐓-𝐜𝐞𝐥𝐥 𝐄𝐧𝐠𝐢𝐧𝐞𝐞𝐫𝐢𝐧𝐠:
◆ 𝐒𝐮𝐛𝐬𝐞𝐭 𝐢𝐬𝐨𝐥𝐚𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐞𝐧𝐫𝐢𝐜𝐡𝐦𝐞𝐧𝐭: CD4+, CD8+, or mixed T-cell populations from autologous or allogeneic sources
◆ 𝐄𝐓𝐄𝐒 𝐦𝐨𝐝𝐮𝐥𝐞 𝐝𝐞𝐥𝐢𝐯𝐞𝐫𝐲: Viral (lentiviral, retroviral) and non-viral (electroporation, lipid nanoparticle) options assessed per construct and program requirements
◆ 𝐈𝐧𝐭𝐞𝐠𝐫𝐚𝐭𝐢𝐨𝐧 𝐞𝐟𝐟𝐢𝐜𝐢𝐞𝐧𝐜𝐲 𝐜𝐨𝐧𝐟𝐢𝐫𝐦𝐞𝐝 𝐛𝐲 flow cytometry and sequencing; transduced cell phenotype and viability validated pre-expansion

𝐓-𝐜𝐞𝐥𝐥 𝐌𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠:
◆ 𝐒𝐜𝐚𝐥𝐚𝐛𝐥𝐞 𝒆𝒙 𝒗𝒊𝒗𝒐 𝐞𝐱𝐩𝐚𝐧𝐬𝐢𝐨𝐧 under optimized, feeder-free culture conditions and cytokine formulation tailored per cell subset
◆ 𝐏𝐡𝐞𝐧𝐨𝐭𝐲𝐩𝐢𝐜 𝐦𝐨𝐧𝐢𝐭𝐨𝐫𝐢𝐧𝐠 at defined process checkpoints, including CD4/CD8 ratio, memory/effector distribution, exhaustion markers
◆ 𝐑𝐞𝐥𝐞𝐚𝐬𝐞 𝐭𝐞𝐬𝐭𝐢𝐧𝐠 𝐩𝐚𝐜𝐤𝐚𝐠𝐞: ETES expression, functional potency (IFN-γ, IL-2, antigen-stimulated cytotoxicity), sterility, and viability
◆ 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐛𝐚𝐭𝐜𝐡 𝐫𝐞𝐜𝐨𝐫𝐝𝐬 structured to support IND-enabling study entry
◆ 𝐂𝐨𝐦𝐩𝐚𝐭𝐢𝐛𝐥𝐞 with both autologous and allogeneic/off-the-shelf T-cell formats

Learn more: https://www.alfacytology.com/etes/t-cell-manufacturing.html